RecruitingPhase 2NCT06949800

CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial

Probiotics to Treat HSIL and Reduce Persistent High Risk HPV Infection in Women and Men Living With HIV

Sponsor

University of California, San Francisco

Enrollment

90 participants

Start Date

Sep 4, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This study is focused on treatment of anal high-grade squamous intraepithelial lesions (HSIL) in persons with HIV (PWH), with the ultimate goal of applying the approach toward prevention of anal cancer in this population

Eligibility

Min Age: 21 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called EXE-346 Probiotic, a drug called Placebo, and others for people with anal hsil, hpv-related squamous cell carcinoma, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 21 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.